[Form 4] Salarius Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Salarius Pharmaceuticals, Inc. (SLRX) director reports stock purchase. A trust associated with director Arnold C. Hanish bought 5,000 shares of Salarius common stock on 11/20/2025 at a weighted average price of $0.7481 per share. These shares were acquired in multiple trades at prices ranging from $0.7437 to $0.75. After this transaction, the trust beneficially owned 5,015 shares of Salarius common stock, reported as indirect ownership on the Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HANISH ARNOLD C

(Last) (First) (Middle)

C/O SALARIUS PHARMACEUTICALS, INC.

2450 HOLCOMBE BLVD., SUITE X

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Salarius Pharmaceuticals, Inc. [ SLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		P		5,000	A	$0.7481(1)	5,015	I	By Arnold C. Hanish Trust
Common Stock								12	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7437 to $0.75, inclusive. The reporting person undertakes to provide to Salarius Pharmaceuticals, Inc., any security holder of Salarius Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

Remarks:

	/s/Mark Rosenblum, as Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Salarius Pharmaceuticals (SLRX) report on this Form 4?

The filing reports that a trust associated with director Arnold C. Hanish purchased 5,000 shares of Salarius Pharmaceuticals common stock on 11/20/2025.

At what price were the Salarius (SLRX) shares purchased by the director’s trust?

The shares were bought at a weighted average price of $0.7481 per share, with individual trades executed between $0.7437 and $0.75 per share.

How many Salarius (SLRX) shares does the reporting person beneficially own after the transaction?

Following the reported purchase, the trust beneficially owned 5,015 shares of Salarius Pharmaceuticals common stock, reported as indirect ownership.

What is the relationship of the reporting person to Salarius Pharmaceuticals (SLRX)?

The reporting person is a director of Salarius Pharmaceuticals, and the shares are held indirectly through the Arnold C. Hanish Trust.

Were the Salarius (SLRX) insider purchases made in a single trade or multiple trades?

The filing explains that the 5,000 shares were purchased in multiple transactions at prices ranging from $0.7437 to $0.75 per share.

Who signed the Salarius (SLRX) Form 4 reporting this insider transaction?

The Form 4 was signed by /s/ Mark Rosenblum as Attorney-in-Fact for the reporting person on 11/24/2025.